|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Bayer |
| Information provided by: | Bayer |
| ClinicalTrials.gov Identifier: | NCT00651599 |
Purpose
Study to demonstrate that the therapeutic efficacy of Angeliq® is superior to placebo in Korean postmenopausal women with hot flushes and other climacteric symptoms.
Safety and tolerability of Angeliq®.
| Condition | Intervention | Phase |
|
Vasomotor Symptoms |
Drug: Angeliq® (2 mg drospirenone and 1 mg estradiol) Drug: Placebo |
Phase III |
| MedlinePlus related topics: | Menopause |
| ChemIDplus related topics: | Depogen Estradiol Estradiol 3-benzoate Estradiol acetate Estradiol cypionate Estradiol dipropionate Estradiol valerate Polyestradiol phosphate 1,2-Dihydrospirorenone |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Tolerability of Angeliq(drospirenon2mg and Estradiol 1mg) in Postmenopausal Korean Women With Vasomotor Symptoms Over 3, 28 Day Treatment Cycle |
| Enrollment: | 72 |
| Study Start Date: | July 2004 |
| Study Completion Date: | May 2005 |
| Arms | Assigned Interventions |
|
Arm 1: Experimental
n/a
|
Drug: Angeliq® (2 mg drospirenone and 1 mg estradiol)
Treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
|
|
Arm 2: Placebo Comparator
n/a
|
Drug: Placebo
Treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
|
Eligibility
| Ages Eligible for Study: | 45 Years to 65 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Responsible Party: | ( Bayer Schering Pharma AG, Therapeutic Area Head ) |
| Study ID Numbers: | 91354, 308381 |
| First Received: | April 1, 2008 |
| Last Updated: | April 2, 2008 |
| ClinicalTrials.gov Identifier: | NCT00651599 |
| Health Authority: | South Korea: Korea Food and Drug Administration (KFDA) |
|
|
|
|
|